Therefore, we hypothesized that overexpression of the ASPH protein could be a major factor for CCA development and progression; and targeting this enzyme with a potent second generation small molecule inhibitor (SMI) of β-hydroxylase activity that was developed by rational drug design based on the crystal structure of the catalytic site, would constitute a novel therapeutic approach for CCA. This evidence concerns the gene ASPH and cholangiocarcinoma.